Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study
Objective To determine the ideal conditions for use of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older outpatients with chronic pulmonary diseases.Design Prospective cohort study.Participants 1378 outpatients with chronic pulmonary diseases ≥60 years of age.Intervention Participan...
Saved in:
| Main Authors: | Satoshi Morita, Satoshi Inoue, Takashi Sato, Yoshiaki Ishigatsubo, Shunsaku Mizushima, Yuji Watanuki, Tetsuji Kaneko, Naoki Miyazawa, Takeshi Kaneko, Yutaka Natsumeda |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2011-09-01
|
| Series: | BMJ Open |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Use of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Rheumatoid Arthritis
by: M. S. Naumtseva, et al.
Published: (2015-08-01) -
EFFICACY AND SAFETY OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: M. S. Naumtseva, et al.
Published: (2015-05-01) -
Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis.
by: Gerhard Falkenhorst, et al.
Published: (2017-01-01) -
Safety and efficacy of 23-valent polysaccharide pneumococcal vaccine in patients with systemic lupus erythematosus
by: G. M. Tarasova, et al.
Published: (2021-06-01) -
ASSESSMENT OF THE IMMUNOGENICITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATIC DISEASES
by: M. S. Naumtseva, et al.
Published: (2016-02-01)